bioAffinity Technologies, a San Antonio, TX-based company advancing early-stage cancer diagnostics and precision therapeutics has raised more than $4 million in Series A funding. The Series A fund reflects its progress toward commercialization in 2018 of the Company’s initial diagnostic product, a non-invasive, early-stage lung cancer test called CyPath® Lung to detect lung cancer in its earliest stages when it is most treatable.
The porphyrin-based CyPath® preferentially binds to cancer cells and labels them with distinct fluorescence for detection by flow cytometry. Research and optimization of its platform technology are conducted in bioAffinity Technologies’ laboratories and at UT Health at San Antonio through a collaborative research agreement.
“We remain focused on the development of safer, more effective cancer diagnostics including CyPath® Lung, a patient-friendly test to detect lung cancer at its earliest stages when treatment is most effective,” said bioAffinity President and CEO Maria Zannes in a statement. “Series A investments will propel our lung cancer diagnostic to commercialization and further our development of additional cancer tests and novel therapeutics that will treat cancer more effectively.”
